Streetbeat News

Regulatory

NVAX

Novavax's COVID-19 vaccine for 2024-2025 has received Emergency Use Authorization from the FDA and is recommended by the CDC for individuals aged 12 and older. It is the only protein-based COVID-19 vaccine available in the U.S. and will be distributed widely in pre-filled syringes.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 7:48 pm

BA

Boeing's new CEO, Kelly Ortberg, had a meeting with FAA Administrator Whitaker earlier this week, as reported by Reuters citing an agency official.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 7:41 pm

HUM

Sanford Health has announced it will end its participation with Humana Medicare Advantage plans effective December 31, citing issues with coverage denials and care delays. Patients are advised to explore other plans during the Medicare open enrollment period.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 7:25 pm

LMT

SPY

The U.S. State Department has approved a potential $390 million sale of High Mobility Artillery Rocket Systems (HIMARS) to Croatia, as reported by Reuters citing the Pentagon.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 7:13 pm

NVAX

Novavax announced that the FDA has authorized its updated COVID-19 vaccine, which is designed to offer better protection against currently circulating variants.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 6:28 pm

EWC

SPY

The U.S. Trade Representative has requested trade dispute settlement consultations with Canada over a new digital services tax, which is considered discriminatory and potentially in violation of the USMCA. If unresolved within 75 days, a dispute settlement panel may be sought.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 6:01 pm

CRWD

CrowdStrike Holdings, Inc. (NASDAQ:CRWD) shares are trading higher as a senior associate is set to testify before Congress regarding a global IT outage in July. The outage affected various industries, and the company has since implemented changes to prevent future incidents.

Portfolio Pulse from Nabaparna Bhattacharya

August 30, 2024 | 5:55 pm

ACI

JNJ

KVUE

RADCQ

Kenvue Inc. (NYSE:KVUE) successfully defended against a lawsuit claiming its Tylenol 'Rapid Release' gelcaps misled consumers. The court ruled in favor of Kenvue, citing FDA regulations. This decision reinforces FDA's authority over drug labeling.

Portfolio Pulse from Vandana Singh

August 30, 2024 | 5:47 pm

BBIO

PFE

BridgeBio Pharma's stock rose after presenting positive data from its Phase 3 study of acoramidis for ATTR-CM at the ESC 2024. The company has submitted a marketing application to the FDA, with a decision expected by November 29, and to the European Medicines Agency, with a decision in 2025. BridgeBio has also partnered with Bayer for commercialization in Europe.

Portfolio Pulse from Vandana Singh

August 30, 2024 | 5:10 pm

RTX

The U.S. State Department has announced a $200 million settlement with RTX Corporation over export violations. This settlement addresses issues related to the company's compliance with export regulations.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 4:26 pm